LEADER 04903nam 22005655 450 001 9910349451403321 005 20200703023510.0 010 $a3-030-16373-3 024 7 $a10.1007/978-3-030-16373-0 035 $a(CKB)4100000008869906 035 $a(MiAaPQ)EBC5844318 035 $a(DE-He213)978-3-030-16373-0 035 $a(PPN)238486176 035 $a(EXLCZ)994100000008869906 100 $a20190730d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPolymyxin Antibiotics: From Laboratory Bench to Bedside /$fedited by Jian Li, Roger L. Nation, Keith S. Kaye 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (364 pages) $cillustrations 225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1145 311 $a3-030-16371-7 327 $aOverview -- Multidrug resistant Gram-negative pathogens: the urgent need for ?old? polymyxins -- Discovery, antibacterial spectrum and chemistry -- Mechanisms of antibacterial activity -- Mechanisms of resistance -- Bioanalysis and stability of polymyxins -- In vitro pharmacodynamics and PK/PD in animals -- Antibacterial susceptibility breakpoints -- Labeling of parenteral products of colistin methanesulfonate -- Meta-analysis of polymyxin use in patients -- Clinical use of colistin -- Clinical use of polymyxin B -- Pharmacokinetics, pharmacodynamics, toxicodynamics and dosing recommendations -- Rational combinations with other antibiotics -- Toxicities in patients: management and mechanisms -- Antiendotoxin effect -- Discovery of novel polymyxin-like antibiotics -- Conclusion. 330 $aThis volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field. It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research. This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative ?superbugs?. 410 0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1145 606 $aBacteriology 606 $aPharmacotherapy 606 $aDrug resistance 606 $aBacteriology$3https://scigraph.springernature.com/ontologies/product-market-codes/L23012 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 606 $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020 615 0$aBacteriology. 615 0$aPharmacotherapy. 615 0$aDrug resistance. 615 14$aBacteriology. 615 24$aPharmacotherapy. 615 24$aDrug Resistance. 676 $a615.329 676 $a615.7922 702 $aLi$b Jian$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aNation$b Roger L$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aKaye$b Keith S$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910349451403321 996 $aPolymyxin Antibiotics: From Laboratory Bench to Bedside$92184146 997 $aUNINA